Multivariate analysis of the Nordic MCL2 and MCL3 trials showed that the presence of TP53 mutations predicted worse overall survival in younger patients with mantle cell lymphoma.
Some patients with mantle cell lymphoma can delay treatment without experiencing negative outcomes, according to findings from a population-based study.
Patients who received maintenance therapy with rituximab (Rituxan) following autologous stem cell transplantation as treatment for mantle cell lymphoma had a survival advantage, according to results from a retrospective single-center study.
In a pooled analysis, investigators determined that ibrutinib (Imbruvica) induced an objective response rate of 66% in patients with mantle cell lymphoma.
Patients with newly diagnosed mantle cell lymphoma assigned to frontline chemotherapy had a survival advantage when they were able to receiver higher dose intensities of bortezomib (Velcade).
Long-term results from the Nordic MCL2 and MCL3 trials showed patients with mantle cell lymphoma who are positive for minimal residual disease following allogenic stem cell transplant had significantly shorter survival.
The FDA has granted a priority review to a new drug application for acalabrutinib for patients with previously-treated mantle cell lymphoma.
The FDA has granted acalabrutinib a breakthrough therapy designation for patients with previously-treated mantle cell lymphoma.
Five-year follow-up from the BRIGHT study confirmed that bendamustine plus rituximab is associated with improved progression-free survival compared with R-CHOP or R-CVP in patients with mantle cell lymphoma or indolent non-Hodgkin lymphoma.
Phase III results from the RAY trial showed that patients with mantle cell lymphoma treated with ibrutinib (Imbruvica) had superior quality of life compared with patients treated with temsirolimus.